Toll-like receptors and myocardial contractile dysfunction

Cardiovascular Research

Volumn 78, Issue 1, 2008, Pages 3-4

  Takahashi, Toshiyuki ^a  

^a JR Tokyo General Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL DNA; CPG OLIGODEOXYNUCLEOTIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOPROTEIN; PEPTIDOGLYCAN; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 9; TOLL LIKE RECEPTOR 9 ANTAGONIST; UNCLASSIFIED DRUG;

DNA DETERMINATION; EDITORIAL; HEART MUSCLE CONTRACTILITY; HUMAN; INFLAMMATION; MOLECULAR RECOGNITION; PRIORITY JOURNAL; PROTEIN ANALYSIS;

ANIMALS; CYTOKINES; HEART FAILURE; HUMANS; IMMUNITY, NATURAL; MYOCARDIAL CONTRACTION; MYOCARDITIS; MYOCARDIUM; NITRIC OXIDE SYNTHASE TYPE II; SEPSIS; TOLL-LIKE RECEPTORS;

EID: 41149174126     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvn044     Document Type: Editorial

References (14)

1. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 2006;124:783-801.
2. de Kleijn D, Pasterkamp G. Toll-like receptors in cardiovascular diseases. Cardiovasc Res 2003;60:58-67.
3. Linde A, Mosier D, Blecha F, Melgarejo T. Innate immunity and inflammation-new frontiers in comparative cardiovascular pathology. Cardiovasc Res 2007;73:26-36.
4. Frantz S, Ertl G, Bauersachs J. Mechanisms of disease: Toll-like receptors in cardiovascular disease. Nat Clin Pract Cardiovasc Med 2007;4:444-454.
5. Frantz S, Kobzik L, Kim YD, Fukazawa R, Medzhitov R, Lee RT et al. Toll4 (TLR4) expression in cardiac myocytes in normal and failing myocardium. J Clin Invest 1999;104:271-280.
6. Ha T, Li Y, Hua F, Ma J, Gao X, Kelley J et al. Reduced cardiac hypertrophy in toll-like receptor 4-deficient mice following pressure overload. Cardiovasc Res 2005;68:224-234.
7. Boyd JH, Mathur S, Wang Y, Bateman RM, Walley KR. Toll-like receptor stimulation in cardiomyoctes decreases contractility and initiates an NF-kappaB dependent inflammatory response. Cardiovasc Res 2006;72:384-393.
8. Vollmer J. TLR9 in health and disease. Int Rev Immunol 2006;25:155-181.
9. Knuefermann P, Schwederski M, Velten M, Krings P, Ehrentraut H, Rüdiger M et al. Bacterial DNA induces myocardial inflammation and reduces cardiomyocyte contractility: role of Toll-like receptor 9. Cardiovasc Res 2008;78:26-35.
10. Shimizu T, Kinugawa K, Sugishita Y, Sugishita K, Harada K, Matsui H et al. Molecular cloning and expression of inducible nitric oxide synthase in chick embryonic ventricular myocytes. Cardiovasc Res 1998;38:405- 413.
11. Annane D, Vignon P, Renault A, Bollaert PE, Charpentier C, Martin C et al. CATS Study Group. Norepinephrine plus dobutamine versus epinephrine alone for management of septic shock: a randomised trial. Lancet 2007;370:676-684.
12. Bhattacharjee RN, Akira S. Modifying toll-like receptor 9 signaling for therapeutic use. Mini Rev Med Chem 2006;6:287-291.
13. Yamada H, Ishii KJ, Klinman DM. Suppressive oligodeoxynucleotides inhibit CpG-induced inflammation of the mouse lung. Crit Care Med 2004;32:2045-2049.
14. Niebauer J, Volk HD, Kemp M, Dominguez M, Schumann RR, Rauchhaus M et al. Endotoxin and immune activation in chronic heart failure: a prospective cohort study. Lancet 1999;353:1838-1842.